The FY24 Defense Appropriations Act provides funding for the LCRP to support innovative, high-impact lung cancer research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.
The FY24 Defense Appropriations Act is anticipated to provide funding for the Ovarian Cancer Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members, and all women impacted by this disease.
The Society for Immunotherapy of Cancer is taking nominations for the SITC Annual Awards and the Academy of Immuno-Oncology.
Yosemite, an oncology-focused venture capital firm, and the American Cancer Society established the Yosemite-American Cancer Society Award with an initial commitment of $13.2 million.
The FY24 Defense Appropriations Act is anticipated to provide funding for the Peer Reviewed Cancer Research Program to support innovative, high-impact cancer research.
The FY24 Defense Appropriations Act provides funding for the Lung Cancer Research Program to support innovative, high-impact lung cancer research.
The Helen F. Graham Cancer Center & Research Institute at ChristianaCare, in partnership with the Wistar Cancer Institute, established a Caspar Wistar Bacchieri Disparities Fellowship in Cancer Population Health Science.
The Indiana University Melvin and Bren Simon Comprehensive Cancer Center was awarded two five-year NCI grants totaling more than $3.3 million to expand its summer education programs, which aim to foster an interest in cancer research fields as early as middle school and develop a diverse workforce in cancer research.
The FY24 Defense Appropriations Act is anticipated to provide funding for the BCRP to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service Members and their Families, Veterans, and the general public.
The Translational Genomics Research Institute, part of City of Hope, established a fellowship in glioblastoma multiforme research. The Lori Lane/Andrew Spyrow Fellowship honors the lives of Lori Lane and Andrew Spyrow who fought GBM bravely, teaching all of us to experience the joy of life and dedicating their journey to the advancement of treatment improving the quality and longevity of life for those facing this devastating cancer.
